Your browser doesn't support javascript.
loading
Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.
Anborgh, Pieter H; Lee, Danny J; Stam, Pieter F; Tuck, Alan B; Chambers, Ann F.
Afiliación
  • Anborgh PH; a London Regional Cancer Program , London, Ontario , Canada.
  • Lee DJ; a London Regional Cancer Program , London, Ontario , Canada.
  • Stam PF; a London Regional Cancer Program , London, Ontario , Canada.
  • Tuck AB; a London Regional Cancer Program , London, Ontario , Canada.
  • Chambers AF; b Departments of Oncology and of Pathology , University of Western Ontario , London, Ontario , Canada.
Expert Opin Ther Targets ; 22(8): 727-734, 2018 08.
Article en En | MEDLINE | ID: mdl-30025479
OBJECTIVE: Effective targeted therapies for patients with triple-negative breast cancer (TNBC) present an unmet clinical need. There is evidence that TNBCs often have increased expression of the epidermal growth factor receptor (EGFR) and of osteopontin (OPN). OPN-mediated signaling can activate EGFR-dependent signaling pathways. Here, we assessed OPN as a potential predictive biomarker for response to anti-EGFR therapy in TNBC. RESEARCH DESIGN AND METHODS: Using two different TNBC cell lines, MDA-MB-468 and MDA-MB-231, we investigated the impact of stable expression of OPN on efficacy of the EGFR inhibitor erlotinib in vitro. RESULTS: We observed that breast cancer cells engineered to overexpress OPN are more sensitive to growth inhibition by erlotinib than control cells. The level of response was related to the level of OPN expression, possibly due to increased phosphorylation status of EGFR Tyr1068. CONCLUSIONS: These results indicate that OPN expression levels are related to sensitivity of TNBC cells to growth inhibition by erlotinib. OPN thus is a promising predictive biomarker for anti-EGFR therapy in breast cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteopontina / Neoplasias de la Mama Triple Negativas / Clorhidrato de Erlotinib Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Expert Opin Ther Targets Asunto de la revista: TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteopontina / Neoplasias de la Mama Triple Negativas / Clorhidrato de Erlotinib Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Expert Opin Ther Targets Asunto de la revista: TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido